CClinicalTrials.gg
CompletedNCT01684800NOCUpdated Aug 23, 2013

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women

A Phase 2 interventional study of A. Desmopressin 10 microgram and B: Desmopressin 25 microgram in Nocturia, sponsored by Ferring Pharmaceuticals. Completed at 36 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-23.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Study summary

The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult women during 12 weeks treatment

02

Conditions studied

  • Nocturia

Browse trials for

03

In context

Nocturia

124 studies on the registry are indexed under Nocturia; 24 are open to participants now.

This study's enrollment of 178 is above the median of 67 across 94 interventional studies indexed under Nocturia.

Browse Nocturia studies →

Lead sponsor

Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Has given written consent prior to any trial-related activity is performed.
  • Female sex, aged 20 years or older.
  • At least 2 nocturnal voids every night in a consecutive 3-day period as documented in the diary during the screening period.
  • Has given agreement about contraception during the trial.

Exclusion criteria

Exclusion Criteria:

  • Showing symptoms of any of the following diseases: Interstitial cystitis; Overactive bladder, defined as >6 daytime voids,≥1 urgency episode and ≥1 urge urinary incontinence episode per 24 hours as documented in the 3-day diary period; Severe stress urinary incontinence.
  • Psychogenic or habitual polydipsia.
  • Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention.
  • Cancer.
  • A history of urologic malignancies or a history of cancer which has not been in remission for the last 5 years.
  • Genito-urinary tract pathology.
  • Neurogenic detrusor activity.
  • Suspicion or evidence of heart failure.
  • Uncontrolled hypertension.
  • Uncontrolled diabetes mellitus.
  • Hepatobiliary diseases: Aspartate aminotransferase >80 U/L or alanine aminotransferase >90 U/L; Total bilirubin >1.5 mg/dL.
  • Renal insufficiency: Serum creatinine level >0.82 mg/dL; Estimated glomerular filtration rate \<50 mL/min.
  • Hyponatraemia: Serum sodium level \<135 mEq/L.
  • Central or nephrogenic diabetes insipidus.
  • Syndrome of inappropriate antidiuretic hormone.
  • Obstructive sleep apnea.
  • Previous desmopressin treatment.
  • Treatment with another investigational product within the past 3 months.
  • Concomitant treatment with any prohibited medication.
  • Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.
  • Alcohol or substance abuse.
  • A job or lifestyle that may interfere with regular night-time sleep.
  • A mental condition, lack of decision-making ability, dementia, a speech handicap, or any other reason which, in the judgement of the investigator (sub-investigator), would impair the participation in the trial.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
178 participants (actual)

Study arms

  • Active comparator
    A. Desmopressin 10 microgram

    Drug: A. Desmopressin 10 microgram

  • Active comparator
    B. Desmopressin 25 microgram

    Drug: B: Desmopressin 25 microgram

  • Placebo comparator
    C. Placebo

    Drug: C: Placebo

Interventions

  • DrugA. Desmopressin 10 microgram

    1 orally disintegrating tablet every night during study period

  • DrugB: Desmopressin 25 microgram

    1 orally disintegrating tablet every night during study period

  • DrugC: Placebo

    1 orally disintegrating tablet every night during study period

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean number of nocturnal voids

    Time frame: During 12 weeks

Secondary outcomes

  1. Change from baseline in mean time to first void

    Time frame: During 12 weeks

  2. Responder status (33% reduction in nocturnal voids)

    Time frame: During 12 weeks

  3. Change from baseline in mean number of nocturnal voids

    Time frame: 1, 4, 8 and 12 weeks

  4. Change from baseline in mean time to first void

    Time frame: 1, 4, 8 and 12 weeks

  5. Responder status (33% reduction in nocturnal voids)

    Time frame: 1, 4, 8 and 12 weeks

  6. Change from baseline in mean nocturnal urine volume

    Time frame: 1, 4, 8 and 12 weeks

  7. Change from baseline in nocturnal polyuria index

    Time frame: 1, 4, 8 and 12 weeks

  8. Change from baseline in the effect on sleep disturbance

    Time frame: 1, 4, 8 and 12 weeks

  9. Change from baseline in the impact on quality of life

    Time frame: 12 weeks

  10. Adverse events, changes from baseline in serum sodium level, laboratory values

    Time frame: During 12 weeks

07

Study locations

36 sites
  • Japanese Red Cross Nagoya Daiichi Hospital
    Aichi, Japan
  • Clinic Tsudanuma
    Chiba, Japan
  • University of Fukui Hospital
    Fukui, Japan
  • Kato Clinic
    Gunma, Japan
  • Umeyama Clinic
    Gunma, Japan
  • Harada Urology Clinic
    Hyogo, Japan
  • Sakaguchi Urological Clinic
    Hyogo, Japan
  • Nakamura Urology Clinic
    Kanagawa, Japan
  • Nishi-Yokohama International Hospital
    Kanagawa, Japan
  • Yokohama Shinmidori General Hospital
    Kanagawa, Japan
  • Izumino Hospital, Bouchikai
    Kochi, Japan
  • Kamei Clinic
    Kochi, Japan
  • Den Urology Clinic
    Osaka, Japan
  • Iwasa Clinic
    Osaka, Japan
  • Kanno Clinic
    Osaka, Japan
  • Morimoto Clinic
    Osaka, Japan
  • Naka Clinic
    Osaka, Japan
  • Uemura Clinic
    Osaka, Japan
  • Urology department Kuroda Clinic
    Osaka, Japan
  • Yamaguchi Clinic
    Osaka, Japan
  • Yamanaka Clinic
    Osaka, Japan
  • Fukuda Clinic
    Saitama, Japan
  • Yasuda Urology Clinic
    Saitama, Japan
  • Hirano Clinic
    Tokyo, Japan
  • Hirata Internal Medicine Urology Clinic
    Tokyo, Japan
  • J Tower Clinic
    Tokyo, Japan
  • Koganeibashi Sakura Clinic
    Tokyo, Japan
  • Kunitachi Sakura Hospital
    Tokyo, Japan
  • Kusunoki Clinic
    Tokyo, Japan
  • Moriguchi Clinic
    Tokyo, Japan
  • Nakanoma Clinic Urology Department
    Tokyo, Japan
  • Ogawa Clinic
    Tokyo, Japan
  • Ogikubo Ekimae Clinic
    Tokyo, Japan
  • Shibuya Shin-minamiguchi Clinic
    Tokyo, Japan
  • Tokyo Kamata Hospital
    Tokyo, Japan
  • Toru Clinic
    Tokyo, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01684800
Lead sponsor
Ferring Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Sep 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Aug 23, 2013

Study contacts

Clinical Development Support
study director · Ferríng Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion